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An intriguing quality of many genetic diseases in humans
is the significant intrafamilial variability observed in
their clinical presentation. It seems to be likely that def-
inition of the factors responsible for such differenceswill
provide important clues to the normal function of the
genes and to the pathobiology of their associated dis-
eases. For some diseases, such as fragile X syndrome and
Huntington disease, it has been shown that genetically
related individuals do not necessarily have identical
germ-line mutations, and instability at the mutant loci
may account for much of the observed clinical variation.
However, these diseases are the exception to the rule,
and other explanations must be sought.
The results of breeding experiments on mice suggest
that variants at other genetic loci may play an important
role in modification of the phenotypic expression of
many mutant genotypes. Transfer of a mutant gene from
one strain to another may greatly alter the severity of
disease. For example, it is well recognized forDrosophila
that, in the heterozygous state, certain recessive alleles
can result in a phenotype if introduced into a genetic
background that has so-called enhancer alleles at other
loci. This strategy has been exploited to dissect out sig-
naling pathways and to identify interacting molecular
partners (Simon et al. 1991). One can easily imagine
how family members who share the same mutant gen-
otype might have different alleles at modifying loci and
thus might present with a milder or a more severe
disease.
However, genetic background is unlikely to explain
all aspects of phenotypic variability in human disease.
This, perhaps, is illustrated best by autosomal dominant
diseases that present with focal manifestations, such as
autosomal dominant polycystic kidney disease (ADPKD)
(Gabow 1993). ADPKD describes a group of at least
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three genetically distinct disorders with essentially iden-
tical phenotypes. The clinical hallmark of this group of
diseases is the focal formation of cysts within the kidney
and liver, which increase in both size and number over
the lifetime of an individual. It is estimated that !5%
of all nephrons (∼106 nephrons per kidney) acquire
cysts. Hepatic cysts, presumed to be derived from the
epithelia of intrahepatic biliary ductules, develop in only
∼40% of affected individuals and vary greatly in num-
ber. Cerebral aneurysms, one of the most feared com-
plications associated with ADPKD, are focal and de-
velop in a relatively small portion of all affected
individuals.
At one point, an unstable mutation had been postu-
lated to explain these findings (Reeders 1992), but, with
the subsequent discovery of the genes for the two most
common forms of ADPKD, PKD1 (chromosome 16;
∼85%) and PKD2 (chromosome 4; ∼15%), this expla-
nation has been ruled out (Burn et al. 1995; Mochizuki
et al. 1996). For either gene, all germ-line mutations that
have been identified thus far have been stable within
families. In one family, for instance, a child with a severe
infantile presentation was shown to carry the same non-
sense mutation of PKD1 as that found in another, clin-
ically unaffected child (Peral et al. 1996).
If every tubular cell within an affected individual’s
kidney or biliary tract inherits the same germ-line mu-
tation and the same alleles at modifying loci, why do
only a small fraction become cystic? Several models are
worth brief consideration. One obvious explanation is
that the temporal and spatial patterns of expression of
the normal gene may determine which tissues are af-
fected. It also is possible that mutations that promote
abnormal patterns of gene expression may confer a phe-
notype specifically on cells in which the mutant gene
product accumulates. The phenotype may reflect the ab-
normal expression pattern of the mutant gene product.
An alternative explanation is that some subsets of cells
have redundant pathways that compensate for the effect
of the mutation. Similarly, disease expression may be
defined by the differential expression of other pathway
components. Local factors such as metabolic load, en-
vironmental milieu, or stochastic effects also may play
an important role. Finally, somatic mutation has been
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shown to be an important second step in the pathogen-
esis of many familial cancer syndromes.
The Two-Hit Model and Cyst Formation in ADPKD
Which of these mechanisms might explain the vari-
ability of focal cyst formation in ADPKD?Recent studies
have provided partial answers to this question, for
PKD1. Although there are conflicting reports regarding
the protein’s pattern of expression, it appears to be likely
that the PKD1 gene product, polycystin, is widely ex-
pressed in both fetal and adult tissues and appears to be
more abundant in cystic tissue (Bacallao and Carone
1997). These data have been interpreted by some to
suggest that PKD1 mutant products must act by means
of a gain-of-function or a dominant-negative mecha-
nism. However, if either mechanism is to blame, the nor-
mal pattern of expression does not easily explain why
cysts are focal. These observations suggest that cyst for-
mation requires at least two steps, an inherited suscep-
tibility and a subsequent so-called activating event,
which is rate limiting.
Recent data from our laboratory (Qian et al. 1996),
which were corroborated by Brasier and Henske (1997),
suggest that the second step in the pathogenesis of PKD1
is likely to be an acquired mutation of the normal allele
of the PKD1 gene. We developed a new method for
isolating DNA from the epithelial cells lining single renal
cysts and used it to show that renal cysts in ADPKD are
monoclonal. We demonstrated loss of heterozygosity
(LOH) within individual cysts, for two closely linked
polymorphic markers located within the PKD1 gene.
Genetic analysis confirmed that the normal haplotype
was lost or mutated, in somatic tissues. Brasier and Hen-
ske (1997), using two different techniques (primary cell
culture and cyst scraping), reported similar findings.
On the basis of a relatively low rate of detection of
LOH (∼20% of cysts), some have suggested that the
phenomenon may be a consequence of the cystic state
rather than an important step in its pathogenesis (Ong
and Harris 1997). Somatic involvement of the neigh-
boring TSC2 gene also had been suggested as a possible
explanation. Although more data will be required in
order to resolve the matter, several pieces of evidence
support the so-called two-hit genetic model, for PKD1.
First, it is very likely that the low rate of detection reflects
the limits of our ability to identify mutations rather than
a lack of somatic mutation. Indeed, one of the cyst sam-
ples had acquired a 2-bp deletion in exon 46 in its nor-
mal allele, a lesion that would have been overlooked by
focusing on large-scale deletions that affect markers
linked to PKD1 (Qian et al. 1996). We subsequently
have discovered other subtle intragenic mutations that
appear to represent so-called second hits in cyst for-
mation (T. Watnick, personal communication). It is im-
portant to note that only a small number of germ-line
mutations have been reported since the initial report of
the gene’s sequence, in 1994, despite intense screening
by many groups (The European Polycystic Kidney Dis-
ease Consortium 1994; Peral et al. 1997; Watnick et al.
1997). Second, the discovery that the somatic mutations
can be intragenic argues against a role for TSC2 in the
pathogenesis. Finally, somatic mutation was found to
have altered the normal haplotype in all cysts for which
a haplotype could be determined (10/10 cysts). The
probability that this could occur by chance is !1/1,000.
An obvious question is whether a similar two-step
process is responsible for cyst formation in the other
forms of ADPKD. The essentially indistinguishable clin-
ical presentation of the three forms suggests that this is
likely to be the case. Although germ-line mutations af-
fecting PKD2 and PKD3 undoubtedly are responsible
for the so-called first hit in the respective forms of
ADPKD (Mochizuki et al. 1996), the nature of the sec-
ond events is not yet known. An important consideration
is the extraordinary number of somatic mutations that
apparently must occur to account for the number of cysts
observed (102 to 104). For PKD1, we speculated that an
unusual polypyrimidine tract within intron 21 of the
gene might be responsible for both the high frequency
of the disease within the population and the large num-
ber of second hits observed in cystic epithelia (Qian et
al. 1996). For PKD2, however, no similar elements have
been discovered.
The apparently high rate of cyst formation in PKD2
and PKD3 implies one of two possibilities: (1) the sec-
ond-hit rates of PKD1, PKD2, and PKD3 reflect the
average rate of somatic mutation in the genome rather
than an unusually high rate of somatic mutation result-
ing from a locally mutable structure within each gene,
or (2) somatic inactivation of PKD1 may be the second
step that leads to clonal expansion in the other forms
of ADPKD. Reports showing that the PKD1 and PKD2
gene products are likely to interact is consistent with the
latter hypothesis (Qian et al. 1997). This model predicts
that the relative frequencies of the forms of the disease
in the population are determined by the rate of germ-
line mutation at each genetic locus, whereas the fre-
quency with which cysts form in each disorder is deter-
mined by the rate of somatic mutation of PKD1. Further
study is required, to distinguish between the twomodels.
The results may have important implications for inves-
tigators interested in the problem of somatic mutability.
The Two-Hit Model in Other Nonmalignant Diseases
These observations suggest that ADPKD is one of a
growing list of disorders to which the two-hit model,
first proposed by Knudson (1971) to explain the origin
of retinoblastoma, seems to apply. Although most ex-
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amples involve tumor-suppressor genes implicated in the
origin of various other types of cancer, it increasingly
has been recognized that benign tumors may develop by
a similar mechanism. The tumors that develop in indi-
viduals suffering from either tuberous sclerosis (TSC)
(type I or type II) or neurofibromatosis type I (NF1) are
examples.
TSC is an autosomal dominant trait that, like
ADPKD, is characterized by significant intrafamilial phe-
notypic variability and focal manifestations. One hall-
mark of the disease is the development of benign tumors,
known as “hamartomas,” in multiple organs. LOH has
been found for markers flanking the loci for TSC1 (chro-
mosome 9q34) and TSC2 (chromosome 16p13.3). A
study by Sampson et al. (1997), reported in the October
issue of the Journal, suggests that the two-hit mechanism
may be involved in causing other clinical manifestations
in TSC2. The authors studied 27 patients with TSC and
multiple bilateral renal cysts. They found that 22 pa-
tients had contiguous gene deletions that removed siz-
able portions of PKD1 and TSC2, 3 had gross rear-
rangements involving only TSC2, and 2 had no
detectable mutations of TSC2. Since no significant cystic
disease had been documented for the affected members
of the TSC1 families, the authors concluded that sig-
nificant renal cystic disease in TSC usually reflects mu-
tational involvement of PKD1. We speculate that so-
matic mutation of PKD1 is also likely to be discovered
in the renal cysts of patients with TSC. In addition, one
might speculate that some of the other uncommon ex-
trarenal manifestations of TSC that are also observed in
PKD1—such as hepatic cysts, cerebral and aortic an-
eurysms, and cardiac valvular disease—might arise by a
similar mechanism.
For NF1, the malignancies that complicate this disease
were thought to follow the two-hit hypothesis, but the
etiology of the benign tumors was less clear, since a
number of studies initially failed to detect LOH in neu-
rofibromas. Demonstration of LOH for chromosome
17q11 markers in the benign neurofibromas was more
difficult, because the lesions were comprised of an ad-
mixture of cell types. Colman et al. (1995) resolved the
matter by using a panel of intragenic markers to dem-
onstrate a decrease in signal intensity for alleles of a
haplotype in the tumor DNA. Sawada et al. (1996) sub-
sequently identified a 4-bp somatic deletion inNF1 exon
4b of the previously normal allele from a microdissected
benign neurofibroma with a known constitutional germ-
line mutation.
One disease that recently has been proposed as an
excellent candidate for the two-hit model is hereditary
hemorrhagic telangiectasia (HHT), an autosomal dom-
inant disease of blood vessels, characterized by muco-
cutaneous telangiectasias and vascular malformations in
the lung and brain. The lesions are discrete, appear in
a random distribution, and increase in size and number
with the age of the individual. In most families, the dis-
ease arises from mutations of either (1) ENG, the gene
for endoglin, a TGF-b (transforming growth-factor b)
binding protein of endothelial cells (HHT1) (Shovlin et
al. 1997), or (2) ALK-1, which encodes a type I receptor
of the TGF-b superfamily (HHT2) (Berg et al. 1997).
The results of the studies by Shovlin et al. (1997) and
Berg et al. (1997) suggest that mutations of both ENG
and ALK-1 result in functionally null alleles. In two
individuals with HHT2, the mutant mRNA was absent
or hardly detectable, by reverse-transcriptase PCR, in
the cDNA of peripheral blood leukocytes. Similarly, a
stable mutant ENG transcript was not produced in lym-
phocytes of two individuals with HHT1. Five other
HHT1 mutations were discovered to produce severely
altered mRNAs that were predicted to encode greatly
truncated proteins.
Whereas Shovlin et al. (1997) suggested that haploin-
sufficiency is likely to be the mechanism of disease for
HHT1, Berg et al. (1997) proposed a two-hit mechanism
for HHT2, on the basis of the focal nature of the disease.
They noted, however, that this hypothesis may be very
difficult to prove. The telangiectasias appear to result
from dilatation of blood vessels rather than from pro-
liferative growth, and loss of ALK-1 function may in-
duce remodeling of the vascular bed rather than alter-
ation of the rate of endothelial cell proliferation. LOH
or somatic mutation may occur only in the single layer
of endothelium lining the structure. Berg et al. (1997)
acknowledged that formal proof of their hypothesis will
require the use of methods that are capable of isolating
relatively pure populations of the endothelial cells that
line the vascular malformation. Given the overlap in the
clinical presentations of HHT1 and HHT2, one must
consider a two-hit model for HHT1 as well.
The PKD1 and NF1 examples illustrate one of the
difficulties often faced by investigators seeking to iden-
tify somatic mutations. Focal lesions often are small and
lack clear boundaries with the surrounding normal tis-
sue. Moreover, the cells in these structures frequently are
heterogeneous in origin. Contamination by normal tis-
sue may complicate the analyses and may obscure LOH.
In the case of PKD1, our initial attempts at demonstrat-
ing clonality for cysts failed when we used microdissec-
tion techniques to isolate the epithelia, because the cyst
walls contained nonepithelial cells. Thus, in the patho-
genesis of the focal manifestations of diseases other than
cancers, somatic mutation may play a role that is much
more common than has been shown heretofore.
The Two-Hit Model and the Haploinsufficient State
These observations prompt one to consider whether
somatic mutations also might play a role in the patho-
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genesis of other diseases for which haploinsufficiencyhas
been proposed as the molecular mechanism. Fisher and
Scambler (1994) previously suggested this possibility, to
account for the phenotypic variability observed in at
least some of the haploinsufficiency syndromes. Fisher
and Scambler cited the CATCH22 (cardiac defect, ab-
normal facies, thymic hypoplasia, cleft palate, hypocal-
cemia, and 22q11 deletion) syndrome as an example for
which the clinical features could be explained nicely by
a two-hit process. Fisher and Scambler suggested that
the pattern of disease might be determined by the specific
cell lineage affected by the second hit. Somatic mutation
in one neural-crest line might result in a conotruncal
defect, whereas mutation in another might result in par-
athyroid aplasia.
Holoprosencephaly type 3 (HPE3) is another auto-
somal dominant disorder for which the clinical features
could be explained by a similar process. This disease is
characterized by considerable intrafamilial phenotypic
variability and a broad spectrum of clinical severity.
Roessler et al. (1996) recently reported that loss of one
allele of the sonic hedgehog gene (SHH) is sufficient to
cause the disease in humans, whereas loss of both alleles
is necessary to cause the characteristic phenotype in
mice. Although a species-specific difference in the SHH
pathway cannot be excluded, a two-hit model also could
explain the phenotypic variability. Mice have a smaller
target size and lower general mutation frequency than
those of humans and, thus, may acquire somatic mu-
tations of SHH much less frequently. This difference
could explain why mice with one mutant allele do not
develop abnormalities.
It is reasonable to speculate that somatic mutation
may be required for some forms of piebaldism. This
autosomal dominant disorder of pigmentation is char-
acterized by patches of white skin and hair and is ge-
netically heterogeneous. The KIT proto-oncogene and
its ligand, steel factor, have been implicated in the path-
ogenesis of this disorder. A wide spectrum of mutations
of the KIT proto-oncogene have been described and in-
clude both dominant-negative and null alleles (Spritz et
al. 1992). One explanation for the apparent paradox is
that the pathway is exquisitely sensitive to the level of
functional protein. The two-hit model provides an at-
tractive alternative solution. The likely net effect of a
dominant-negative mutation is a reduction of functional
activity much below that seen in the haploinsufficient
state. A similar decrease in net functional activity may
result in cells with null alleles only after they have ac-
quired a second hit (from either KIT or another gene in
its pathway).
Crosby et al. (1993) proposed the same phenomenon
as an explanation for the origin of sporadic congenital
anomalies in mice with the so-called disorganization
(Ds) mutation. The Ds mutation results in a dominant
condition with variable expression and incomplete pen-
etrance, presenting with a wide range of congenital ab-
normalities. Crosby et al. showed that the occurrence of
the abnormalities in Ds mice followed a Poisson distri-
bution, suggesting that multiple anomalies in a given
mouse result from independent second events. The truly
dominant nature of the Ds mutation suggests that the
second events are likely to be somatic mutations affect-
ing other genes.
Somatic Mutation and Clinical Variability
These data lend further support to the hypothesis that,
in phenotypic variation and perhaps even in the aging
process, somatic mutation may play a role much larger
than previously suspected. Whereas most acquired mu-
tations are expected to be silent in diploid organisms, a
number of situations might allow these effects to be
manifested:
1. Germ-line mutations, such as those in Ds (or
PKD2?), might combine with a somatic mutation that
disrupts the function of an interacting partner or a path-
way member in a manner analogous to that observed
for enhancer alleles in Drosophila (Simon et al. 1991).
2. The somatic mutation might inactivate the second
allele in a heterozygous individual. Virtually all individ-
uals are likely to be heterozygous carriers for multiple
recessive alleles. Cell lineages that acquire somatic mu-
tations at any of these loci might be predicted to express
a recessive phenotype. In some genes, this might result
in cell death and gradual loss of organ function (partic-
ularly if the cells are not proliferative, such as with ma-
ture neurons). In developmental pathways, focal loss
could reduce the number of progenitor cells, with var-
iable consequences.
3. The mutation might occur at a locus that is subject
to X inactivation. This group of genes is functionally
hemizygous. Cells that acquire inactivating mutations
affecting any gene that undergoes X inactivation will
lose that gene’s function. Paroxysmal nocturnal hemo-
globinuria (PNH) is a well recognized example of this
phenomenon. The PNH abnormality has been demon-
strated to be due to a somatic mutation of the X-linked
PIG-A gene (Bessler et al. 1994). The disease does not
show sex preference, because the acquired mutation oc-
curs after X-chromosome inactivation.
4. The somatic mutation might result in products with
a true dominant or dominant-negative activity. The role
of acquired activating mutations of various proto-on-
cogenes has been well established in the origin of cancer.
McCune-Albright syndrome is another example of this
phenomenon. This sporadic disease is characterized by
polyostotic fibrous dysplasia, cafe-au-lait pigmentation
of the skin, and multiple endocrinopathies. It results
from an acquired mutation of the stimulatory G protein,
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Gsa, which occurs early in development and causes a
mosaic population of cells (Weinstein et al. 1991). The
pattern of expression of the disease is determined by the
number and location of cells bearing the mutation.
This discussion naturally leads to the final question:
how frequently do somatic mutations actually occur?
The rate would greatly determine the relative role this
process has in contributing to normal phenotypic vari-
ation, the pathogenesis of disease, or the biology of ag-
ing. ADPKD may offer a unique opportunity to study
this problem in vivo (but, see Tischfield 1997 [in this
issue] for a complementary approach using primary cell
culture). As noted earlier, the three forms of the disease
have identical patterns of disease expression, with rel-
atively similar rates of cyst formation (PKD2 may be
slightly milder). If analysis of PKD2 and PKD3 cysts
reveals LOH for their respective genes, the data would
suggest that the rate of somatic mutation at three in-
dependent loci is approximately similar. These results
could provide a minimal estimate of the average rate of
somatic mutation in the human genome, in at least one
solid organ.
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